Karyopharm Therapeutics (KPTI) Expected to Release Quarterly Earnings on Monday

Karyopharm Therapeutics (NASDAQ:KPTI) is expected to be releasing its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Karyopharm Therapeutics to announce earnings of ($1.37) per share and revenue of $33.12 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 8:00 AM ET.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, May 14th. The company reported ($1.24) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.21. The business had revenue of $35.07 million during the quarter, compared to analyst estimates of $31.40 million. On average, analysts expect Karyopharm Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Karyopharm Therapeutics Trading Up 0.3%

KPTI stock traded up $0.01 on Monday, hitting $1.93. The company’s stock had a trading volume of 1,429,855 shares, compared to its average volume of 890,317. The stock has a market cap of $43.62 million, a price-to-earnings ratio of -0.13 and a beta of 0.90. The firm has a 50 day moving average of $8.88 and a two-hundred day moving average of $8.19. Karyopharm Therapeutics has a 1 year low of $1.80 and a 1 year high of $10.99.

Analyst Ratings Changes

A number of equities research analysts have recently commented on KPTI shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Karyopharm Therapeutics in a report on Tuesday, June 9th. HC Wainwright lowered Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a report on Friday. Weiss Ratings downgraded Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Robert W. Baird downgraded Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research note on Friday. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $11.50.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KPTI. Baird Financial Group Inc. purchased a new stake in Karyopharm Therapeutics during the 2nd quarter worth about $45,000. XTX Topco Ltd acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $56,000. Corient Private Wealth LLC acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at approximately $74,000. Tudor Investment Corp ET AL purchased a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $95,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Karyopharm Therapeutics during the fourth quarter worth approximately $135,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.